Sanofi receives EU clearance to acquire Boehringer Ingelheim consumer health unit

Sanofi's plan to take ownership of Boehringer Ingelheim's consumer health division has been approved by the European Commission.

The European regulatory body has signed off on the proposed acquisition under the EU Merger Regulation, though approval is conditional upon the divestment of a number of business interests in the Czech Republic, Estonia, France, Hungary, Greece, Ireland, Latvia, Poland and Slovakia.

Nevertheless, the investigation found no competition concerns for the majority of the products the business sells, and Sanofi has agreed to sell off its interests in any assets that could pose a risk of leading to higher prices and reduced choice for customers.

The European Commission's decision brings the companies one step closer to completing their business swap deal, which will see Sanofi take over the Boehringer Ingelheim consumer health business in exchange for ownership of its animal health division Merial.

It is expected that the acquisition will make Sanofi an industry leader in consumer healthcare, while allowing Boehringer Ingelheim to become the second-largest player in the animal health sector.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.